Lexicon Pharmaceuticals (LXRX) Non-Current Assets (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Non-Current Assets data on file, last reported at $82.8 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $82.8 million, up 59.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $329.8 million (up 57.7% YoY), and the FY2025 annual result was $83.1 million, up 59.1% from the prior year.
• Non-Current Assets held at $82.8 million in Q1 2026 per LXRX's latest filing, from $83.1 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $83.4 million in Q3 2025 and troughed at $47.4 million in Q2 2022.
• A 5-year average of $59.1 million and a median of $52.9 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2026: Non-Current Assets dropped 2.04% in 2022, then soared 59.62% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $53.4 million in 2022, then decreased by 1.03% to $52.9 million in 2023, then slipped by 1.24% to $52.2 million in 2024, then surged by 59.1% to $83.1 million in 2025, then slipped by 0.37% to $82.8 million in 2026.
• Business Quant data shows LXRX's Non-Current Assets at $82.8 million in Q1 2026, $83.1 million in Q4 2025, and $83.4 million in Q3 2025.